TL;DR
Researchers have developed a novel class of chloro(trifluoromethyl)aziridine (CTMA) compounds that show promise as selective proteasome inhibitors. These compounds, evaluated through both computational modeling and laboratory experiments, exhibit anti-proliferative activity against leukemia cells without significant toxicity to healthy cells, suggesting a potential new avenue for cancer therapy.
What Problem Does This Paper Address?
The ubiquitin-proteasome pathway (UPP) is a critical cellular machinery responsible for protein degradation, playing a vital role in maintaining cellular homeostasis and regulating processes like cell death. Proteasome inhibitors (PIs) have emerged as important therapeutic agents, particularly in cancer treatment, by disrupting this pathway and inducing cancer cell death. However, existing PIs can suffer from issues like resistance development and a lack of selectivity. While aziridine derivatives are known for their anticancer properties as alkylating agents, their potential as proteasome inhibitors has not been explored. This paper addresses this gap by investigating a new class of aziridine-based compounds, chloro(trifluoromethyl)aziridines (CTMAs), as potential selective proteasome inhibitors.
Methods
The study employed a multi-pronged approach combining computational and experimental techniques:
- In Silico Studies:
- Docking: Molecular docking simulations were performed using AutoDock Vina (implemented in YASARA) to predict the binding modes of CTMAs to the catalytic pocket of the proteasome's β5 subunit (using the PDB ID: 4HRD crystal structure). This helped assess potential binding affinities and interactions.
- Drug-likeness and ADMET Prediction: The SwissADME web platform was used to evaluate the drug-likeness and predict pharmacokinetic properties (ADMET) of the most promising compounds, ensuring they adhere to established rules like Lipinski's and Veber's for oral bioavailability. The PAINS model was also used to flag potential assay interference.
- BOILED-Egg Model: This model was used to graphically represent the predicted human gastrointestinal uptake (HIA) and blood-brain barrier (BBB) penetration.
- In Vitro Assays:
- Proteasome Inhibition Assays: Standard fluorometric methods were used to evaluate the inhibitory activity of CTMAs against the chymotrypsin-like (ChT-L), caspase-like (Casp-L), and trypsin-like (T-L) activities of the human 20S proteasome.
- Cell-Based Cytotoxicity Assays: The anti-proliferative activity of the compounds was assessed using the resazurin reduction assay on two leukemia cell lines: CCRF-CEM (drug-sensitive) and CEM/ADR5000 (multidrug-resistant). Cytotoxicity against healthy peripheral blood mononuclear cells (PBMCs) was also evaluated to determine selectivity.
Datasets
- Protein Data Bank (PDB): The crystal structure of the proteasome β5 subunit (PDB ID: 4HRD) was used for docking studies.
- Human 20S Proteasome: Obtained from a commercial source for in vitro inhibition assays.
- Leukemia Cell Lines: CCRF-CEM and CEM/ADR5000 cell lines were used for cytotoxicity and anti-proliferative assays.
- Healthy PBMCs: Used to assess the selectivity of the compounds.
No new benchmarks or datasets were introduced in this paper.
Key Insights and Ideas
- Aziridines as Proteasome Inhibitors: The study successfully demonstrates that aziridine derivatives, previously known for other anticancer mechanisms, can indeed function as proteasome inhibitors, opening a new chemical space for PI development.
- Non-Covalent Binding: Despite the alkylating nature of aziridines, the in silico studies suggest that these CTMAs bind to the proteasome in a non-covalent manner, which could lead to a milder inhibition mechanism and potentially reduced off-target effects compared to some covalent inhibitors.
- Structure-Activity Relationship (SAR): The research identified key structural features influencing inhibitory activity. Bulky hydrophobic groups attached to the aziridine nitrogen appear to be crucial for effective binding. Specifically, linear conjugated π-systems, like the anthracene moiety in compound 21, conferred the best activity.
- Selectivity for β5 Subunit: Preliminary assays indicated that the tested CTMAs selectively inhibited the β5 subunit (ChT-L activity) of the proteasome, with minimal to no activity against β1 and β2 subunits, suggesting a targeted approach to proteasome inhibition.
- Drug-like Properties: The most active compounds (21 and 22) satisfied Lipinski's and Veber's rules for drug similarity and showed no alerts from the PAINS model, indicating good potential for further development as drug candidates.
Key Results
- In Silico: Docking studies predicted promising binding modes and affinities for several CTMAs, with compounds 21 and 22 showing particularly favorable scores.
- In Vitro Proteasome Inhibition: Compounds 21 and 22 exhibited the highest inhibitory activity against the ChT-L activity of the human 20S proteasome, with IC50 values in the low micromolar range (13.6 and 14.1 µM, respectively).
- In Vitro Cell-Based Assays: Compounds 21 and 22 demonstrated significant anti-proliferative activity against both drug-sensitive (CCRF-CEM) and multidrug-resistant (CEM/ADR5000) leukemia cell lines, with IC50 values in the range of 24-68 µM.
- Selectivity: Importantly, compounds 21 and 22 showed no significant cytotoxicity against healthy peripheral blood mononuclear cells (PBMCs), highlighting their selective action against cancer cells.
- Resistance Profile: Compounds 21 and 22 showed a degree of resistance of 0.95 and 2.06, respectively, in the CEM/ADR5000 cell line compared to CCRF-CEM, suggesting they may be effective against some resistant cell lines.
Limitations and Future Work
- Limitations:
- While promising, the current IC50 values are in the micromolar range, indicating room for improvement in potency.
- The study focused on two specific leukemia cell lines; broader evaluation across different cancer types would be beneficial.
- The non-covalent binding mode, while potentially advantageous, needs further experimental validation.
- Future Work:
- Further optimization of the CTMA scaffold to enhance potency and selectivity.
- In-depth mechanistic studies to fully elucidate the non-covalent binding mode and its implications.
- In vivo studies to assess the efficacy and safety of the lead compounds in animal models.
- Exploration of their potential in combination therapies.
Summary updated